ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
By Dr. Matthew Watson
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its full year 2022 financial results and recent highlights.
Read the original:
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
Related Post
- Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 25th, 2024
- Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 25th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
- Minutes of Annual General Meeting 2024 - May 25th, 2024
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
- Monopar Announces CFO Succession - May 25th, 2024
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
- Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
- IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
- BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
- Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
- Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
- Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
- Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
- Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
- Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
- Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
- Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
- Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
- Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
- Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
- Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
- BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
- Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
- DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
- Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
- Telesis Bio Announces Reverse Stock Split - May 7th, 2024
- Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
- Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
- Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
- Day One Reports First Quarter 2024 Financial Results and Corporate Progress - May 7th, 2024
- Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
- T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
- Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
- T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
- BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
- T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
- argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
- Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
- Sandoz reports first quarter 2024 sales - May 7th, 2024
- Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
- Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
- Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
- Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
- Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
- Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
- BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
- Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
- Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
- Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
- Financière de Tubize - Dividend approval - April 28th, 2024
Global News Feed
Comments Off on ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights |
March 9th, 2023
This author published 5552 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research